Search clinical trials for: non-squamous NSCLC

Total 3598 results

BeiGene

Not yet recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor | Advanced Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Alpha-fetoprotein (AFP)-Producing Gastric Cancer | Extragonadal Yolk Sac Tumors | Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Sun Yat-sen University

Not yet recruiting

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC (CONTINUE)

Lung Cancer, Nonsmall Cell
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (LungCadX)

NSCLC

China
Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC (pre-FLAME)

Non Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NSCLC | Non-small Cell Lung Cancer

Israel
National Cancer Centre, Singapore

Recruiting

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore
National Cancer Center, China

Not yet recruiting

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

NSCLC
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

Clinical Study of 18F-Alfatide Injection PET/CT

Non-Small Cell Lung Cancer NSCLC

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Henan University of Traditional Chinese Medicine

Recruiting

Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Advanced Non Small Cell Lung Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection

NSCLC, Stage I | Disease Free Survival | Pulmonary Function Assessment

China
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Maastricht University Medical Center
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

NSCLC Stage IV | Brain Metastases, Adult

Netherlands
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Uterine Cervical Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Triple Negative Breast Neoplasms | Pancreatic Neoplasm

United States
Twinpig Biolab, Inc.

Not yet recruiting

Clinical Trial of TB511 in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Prostate Cancer
Summit Therapeutics
Akeso

Recruiting

Phase III Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

Canada, United States, Spain, Italy, France, United Kingdom
Changhai Hospital
Shanghai Chest Hospital; Shanghai Changzheng Hospital; First Affiliated Hospital... and other collaborators

Recruiting

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Non-Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Duke University
Regeneron Pharmaceuticals

Not yet recruiting

TOP 2301: Neoadjuvant Chemo for NSCLC

Non Small Cell Lung Cancer
Henan University of Traditional Chinese Medicine

Recruiting

Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

Early Stage Lung Adenocarcinoma

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
Centro di Riferimento Oncologico - Aviano

Recruiting

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)

Non Small Cell Lung Cancer Metastatic | ALK Gene Mutation

Italy
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
Henan Cancer Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung Cancer | Neuroendocrine Carcinoma | Histology Transformation

China
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NSCLC

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

ALK-positive Non-small Cell Lung Cancer | Real World Study

China
7 Hills Pharma, LLC

Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
The First Affiliated Hospital of Dalian Medical...

Recruiting

Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC

Long-Term Effects Secondary to Cancer Therapy

China
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Shanghai Chest Hospital

Recruiting

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Carcinoma | Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Korea, Republic of, United States, Japan, Brazil, Taiwan, Australia, Austria, Canada, Poland, Belgium, United Kingdom, Turkey, Hungary, Germany, India
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Tang-Du Hospital

Recruiting

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

EGF-R Positive Non-Small Cell Lung Cancer | CNS Metastases

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Germany, Taiwan, Australia, China, Korea, Republic of
St. Joseph's Healthcare Hamilton

Not yet recruiting

Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC

Lung Cancer

Canada
Wuhan Union Hospital, China

Not yet recruiting

Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC

Diagnosis

China
The Affiliated Hospital of Qingdao University

Recruiting

Clinical Effects of Absorbable and Non-absorbable Suture in Bronchial Sleeve Resection

Suture, Complication

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Ukraine
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China

Search clinical trials for: non-squamous NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations